A groundbreaking executive order by President Trump is set to expedite marijuana’s reclassification to Schedule III, marking a pivotal shift in federal drug policy.
Story Highlights
- President Trump’s executive order accelerates marijuana’s move to Schedule III.
- This reclassification could transform the cannabis industry, enhancing banking and tax relief.
- No credible evidence supports fentanyl being declared a Weapon of Mass Destruction.
- Rescheduling efforts include a focus on CBD access for patients.
Trump’s Executive Order: A Game Changer for Cannabis Policy
On December 18, 2025, President Donald Trump signed an executive order aimed at expediting marijuana’s transition from Schedule I to Schedule III under the Controlled Substances Act (CSA). This move aligns with recommendations from the Department of Health and Human Services (HHS) and the Drug Enforcement Administration (DEA), which have been advocating for this change based on marijuana’s medical potential and lower abuse risk compared to other Schedule I substances.
The executive order mandates the Attorney General to prioritize the rescheduling process, effectively bypassing previous delays caused by procedural hearings. This decision has been hailed as a significant victory for advocates of cannabis reform, who argue that the reclassification is long overdue and will pave the way for broader acceptance and use of medical marijuana across the United States.
Implications for the Cannabis Industry
The reclassification of marijuana to Schedule III is expected to have profound implications for the cannabis industry. Businesses operating in states where cannabis is legal could see substantial financial benefits, as the change would eliminate the burdensome IRC §280E tax provision that currently disallows standard business deductions. Additionally, this move is set to open up new banking opportunities, allowing cannabis companies to access traditional financial services previously denied to them under federal law.
Industry experts view this as a ‘watershed moment’ that could boost profits by 30-70% for businesses involved in the legal cannabis market. However, while the executive order is a step forward, the full realization of these benefits hinges on the finalization of DEA’s rulemaking process, which remains in progress.
Fentanyl: No WMD Declaration in Sight
Amidst discussions of marijuana rescheduling, some reports inaccurately claimed that fentanyl has been declared a Weapon of Mass Destruction (WMD). However, no factual basis supports this claim. Fentanyl remains classified as a Schedule II substance, and any shift to a WMD designation would require specific legislative or executive action, which has not occurred.
The confusion likely arises from ongoing debates about opioid policies. While fentanyl’s potency and impact on public health are undeniable, its legal status remains unchanged, with no indications from credible sources of a reclassification to WMD status.
Sources:
Federal Cannabis Rescheduling Creates New Banking Opportunities
Federal Marijuana Rescheduling – Moritz Law DEPC
Historic Marijuana Rescheduling to Schedule III – Clark Hill
